S&P 500   4,957.13 (-1.08%)
DOW   37,869.42 (+0.25%)
QQQ   415.59 (-1.85%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
S&P 500   4,957.13 (-1.08%)
DOW   37,869.42 (+0.25%)
QQQ   415.59 (-1.85%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
S&P 500   4,957.13 (-1.08%)
DOW   37,869.42 (+0.25%)
QQQ   415.59 (-1.85%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
S&P 500   4,957.13 (-1.08%)
DOW   37,869.42 (+0.25%)
QQQ   415.59 (-1.85%)
AAPL   165.04 (-1.20%)
MSFT   399.88 (-1.09%)
META   482.06 (-3.93%)
GOOGL   153.91 (-1.35%)
AMZN   174.56 (-2.60%)
TSLA   147.73 (-1.47%)
NVDA   782.23 (-7.62%)
AMD   147.03 (-5.19%)
NIO   3.82 (-4.50%)
BABA   68.94 (+0.09%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.86 (-4.53%)
GE   148.58 (-2.85%)
CGC   8.06 (+2.94%)
DIS   112.30 (-0.12%)
AMC   3.19 (+9.25%)
PFE   25.90 (+2.01%)
PYPL   62.02 (-0.13%)
XOM   119.91 (+1.17%)
NASDAQ:OSMT

Osmotica Pharmaceuticals (OSMT) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.98
$1.49
52-Week Range
N/A
Volume
296,500 shs
Average Volume
396,682 shs
Market Capitalization
$69.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
OSMT stock logo

About Osmotica Pharmaceuticals Stock (NASDAQ:OSMT)

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

OSMT Stock News Headlines

Vanda Pharmaceuticals Inc.
RVL Pharmaceuticals PLC (RVLPQ)
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
What Wall Street expects from Osmotica Pharmaceuticals's earnings
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Osmotica Pharmaceuticals earnings: here's what Wall Street expects
See More Headlines
Receive OSMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Osmotica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
4/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OSMT
Fax
N/A
Employees
302
Year Founded
N/A

Profitability

Net Income
$-79,590,000.00
Net Margins
-138.76%
Pretax Margin
-167.59%

Debt

Sales & Book Value

Annual Sales
$177.88 million
Book Value
$1.50 per share

Miscellaneous

Free Float
59,318,000
Market Cap
$69.47 million
Optionable
Not Optionable
Beta
2.34
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives


OSMT Stock Analysis - Frequently Asked Questions

How were Osmotica Pharmaceuticals' earnings last quarter?

Osmotica Pharmaceuticals plc (NASDAQ:OSMT) issued its quarterly earnings results on Monday, November, 15th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.06. The business earned $2.20 million during the quarter, compared to analysts' expectations of $2.39 million. Osmotica Pharmaceuticals had a negative trailing twelve-month return on equity of 81.23% and a negative net margin of 138.76%. During the same quarter in the previous year, the company posted ($0.14) EPS.

What other stocks do shareholders of Osmotica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Osmotica Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), AbbVie (ABBV), AT&T (T), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), SCYNEXIS (SCYX), Zynerba Pharmaceuticals (ZYNE) and

When did Osmotica Pharmaceuticals IPO?

Osmotica Pharmaceuticals (OSMT) raised $58 million in an IPO on Thursday, October 18th 2018. The company issued 8,300,000 shares at $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities acted as the underwriters for the IPO.

This page (NASDAQ:OSMT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners